Genprex Inc. (NASDAQ: GNPX) Developing Transformative Cancer Therapies

Gene therapies are gaining growing attention within the medical sector.

• Gene therapies help restore or replace the body’s damaged or missing genes.
• Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die.
• Gene therapies are also being developed for ailments such as migraines, skin conditions and hemophilia.

Genprex Inc. (NASDAQ: GNPX) is developing gene therapies for the treatment of cancer, including its initial drug candidate, Oncoprex(TM) immunogene therapy. Spark Therapeutics Inc. (NASDAQ: ONCE) is tackling hereditary diseases through treatments that augment, suppress or replace mutated genes. Dyadic International Inc. (OTCQX: DYAI) uses a fungus-based technology to deliver treatments, initially to humans, and now to animals. TrovaGene Inc. (NASDAQ: TROV) limits the growth of cancer through treatments that limit cell division. Novartis AG (NYSE: NVS) uses adeno-associated viruses as carriers for a range of treatments which are proving safe and effective in clinical trials.